Ocular Therapeutix

Yahoo Finance • 5 hours ago

Ocular Therapeutix, Inc. (OCUL): A Bull Case Theory

We came across a bullish thesis on Ocular Therapeutix, Inc. on r/Valueinvesting by Senior-Preference678. In this article, we will summarize the bulls’ thesis on OCUL. Ocular Therapeutix, Inc.'s share was trading at $8.88 as of February 16t... Full story

Yahoo Finance • 19 hours ago

Ocular Therapeutix (OCUL) Stock Trades Down, Here Is Why

What Happened? Shares of ophthalmology biopharmaceutical company Ocular Therapeutix (NASDAQ:OCUL) fell 8.6% in the afternoon session after a surprisingly hot wholesale inflation report fueled investor concerns about persistent price press... Full story

Yahoo Finance • 11 days ago

Ocular drops after late-stage trial data for wet AMD therapy

[An arrow pointing downwards on top of a pile of US dollar bills.] Ocular Therapeutix (OCUL [https://seekingalpha.com/symbol/OCUL]) lost ~22% in the premarket on Tuesday after the company released data from a late-stage trial evaluating A... Full story

Yahoo Finance • 11 days ago

Biggest stock movers Tuesday: ZIM, CMPS, and more

[Technical Price Chart Data Analysis Showing 2020 Corona Virus Covid-19 Stock Market Crash] Stock futures dipped Tuesday morning amid a holiday-shortened trading week, spotlighting key economic data and corporate earnings ahead. Here are... Full story

Yahoo Finance • 15 days ago

Ocular Therapeutix™ to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026

Ocular to host webcast scheduled for Tuesday, February 17, 2026, at 8:00 AM ET Detailed SOL-1 data to be presented at the 49th Macula Society Annual Meeting BEDFORD, Mass., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NA... Full story

Yahoo Finance • 22 days ago

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix, Inc. BEDFORD, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it h... Full story

Yahoo Finance • 2 months ago

BofA Bullish on Ocular Therapeutix (OCUL) as AXPAXLI Targets Superiority Label and Faster Regulatory Path in Wet AMD

Ocular Therapeutix Inc. (NASDAQ:OCUL) is one of the low priced stocks to buy with high upside potential. On December 12, Bank of America raised the firm’s price target on Ocular Therapeutix to $21 from $18 and maintained a Buy rating on th... Full story

Yahoo Finance • 3 months ago

Healthcare Names Post Strong After-Hours Moves: KYMR, OCUL, POAI Among Top Gainers

(RTTNews) - Several healthcare and biotech names posted notable gains in Friday's after-hours trading session, with momentum driven by clinical updates, recent announcements, and technical rebounds. Kymera Therapeutics Inc. (KYMR) surged... Full story

Yahoo Finance • 5 months ago

Ocular Therapeutix prices $475M stock offering

* Ocular Therapeutix (NASDAQ:OCUL [https://seekingalpha.com/symbol/OCUL]) has priced an offering of 37.9M shares at $12.53 each, aiming to raise gross proceeds of around $475.0 million. * The offering is expected to close on or about O... Full story

Yahoo Finance • 5 months ago

Ocular Therapeutix™ Announces Pricing of Underwritten Offering of Common Stock

BEDFORD, Mass., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (Nasdaq: OCUL) (“Ocular”, the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced the pricing of a... Full story

Yahoo Finance • 5 months ago

Ocular Therapeutix™ Investor Day to Highlight Exceptional AXPAXLI™ Progress Across SOL Program and Detail Registrational Trial Plans to Pursue a Diabetic Retinopathy Label with a Novel Primary Endpoint

SOL-1 superiority trial continues to demonstrate outstanding patient retention and protocol adherence, with no new or unexpected safety signals observed to date; topline data on track for 1Q 2026 Event to detail how robust SOL-R patient s... Full story

Yahoo Finance • 6 months ago

Key deals this week: Ocular Therapeutix, CoreWeave, Air Lease, Cadence and more

Here's a list of key deals reported across sectors this week: Ocular Therapeutix (NASDAQ:OCUL [https://seekingalpha.com/symbol/OCUL]) rose 6% amid takeover [https://seekingalpha.com/news/4492779-ocular-therapeutix-gains-amid-takeover-spec... Full story

Yahoo Finance • 7 months ago

Ocular gets FDA agreement for registrational trial of Axpaxl

[Eye Exam] Geber86/E+ via Getty Images * Ocular Therapeutix (NASDAQ:OCUL [https://seekingalpha.com/symbol/OCUL]) said it got written agreement regarding a registrational trial design from the FDA for the trial of Axpaxl in non-prolifera... Full story

Yahoo Finance • 7 months ago

Ocular Therapeutix secures FDA agreement for diabetic retinopathy trial

BEDFORD, Mass. - Ocular Therapeutix, Inc. (NASDAQ:OCUL), currently valued at $2.19 billion and trading near its 52-week high of $12.65, announced Tuesday it has received a Special Protocol Assessment (SPA) agreement from the U.S. Food and... Full story

Yahoo Finance • 7 months ago

OCULAR THERAPEUTIX INC (NASDAQ:OCUL) Reports Mixed Q2 2025 Earnings Amid Clinical Progress

OCULAR THERAPEUTIX INC (NASDAQ:OCUL [https://www.chartmill.com/stock/quote/OCUL/profile]) reported its second-quarter 2025 financial results, delivering mixed performance relative to analyst expectations. The company's revenue and earnings... Full story

Yahoo Finance • 7 months ago

Ocular Therapeutix stock maintains Strong Buy rating at Raymond James

Investing.com - Raymond James has reiterated its Strong Buy rating and $19.00 price target on Ocular Therapeutix (NASDAQ:OCUL), currently trading at $12.08, following the company’s presentations at the American Society of Retina Specialist... Full story

Yahoo Finance • 7 months ago

Ocular Therapeutix Q2 2025 Earnings Preview

* Ocular Therapeutix (NASDAQ:OCUL [https://seekingalpha.com/symbol/OCUL]) is scheduled to announce Q2 earnings results on Tuesday, August 5th, before market open. * The consensus EPS Estimate is -$0.35 [https://seekingalpha.com/symbol/... Full story

Yahoo Finance • 2 years ago

Ocular Therapeutix™ Announces Proposed Public Offering of Common Stock

Ocular Therapeutix, Inc. BEDFORD, Mass., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix™, Inc. (Nasdaq: OCUL) (the “Company”), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative... Full story

Yahoo Finance • 2 years ago

Ocular Therapeutix™ to Present at Three Upcoming Investor Conferences

BEDFORD, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of th... Full story

Yahoo Finance • 2 years ago

Ocular Therapeutix™ Provides Third Quarter 2023 Financial Results and Corporate Update

FDA Agrees to Overall Design of the First Pivotal Trial for AXPAXLI in Wet AMD under a Special Protocol Assessment; Expect First Subject Dosed by Year-End Top-line Data from U.S.-based HELIOS Trial Evaluating AXPAXLI for Treatment of Non-... Full story